Short Interest in Kamada Ltd. (NASDAQ:KMDA) Rises By 61.8%

Kamada Ltd. (NASDAQ:KMDA) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 56,800 shares, an increase of 61.8% from the February 28th total of 35,100 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 210,800 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of Kamada

Several hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new position in shares of Kamada during the 4th quarter valued at approximately $67,000. Public Employees Retirement System of Ohio purchased a new position in Kamada in the third quarter valued at approximately $77,000. NewEdge Advisors LLC lifted its stake in Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. Geode Capital Management LLC grew its holdings in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,549 shares during the period. Finally, Aristides Capital LLC increased its position in Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the last quarter. Institutional investors own 20.38% of the company’s stock.

Kamada Stock Performance

NASDAQ:KMDA traded down $0.22 during trading on Monday, reaching $6.53. The company’s stock had a trading volume of 94,943 shares, compared to its average volume of 79,259. Kamada has a 12 month low of $4.74 and a 12 month high of $9.16. The firm has a market cap of $375.34 million, a price-to-earnings ratio of 23.23, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97. The firm has a 50 day moving average of $7.17 and a 200-day moving average of $6.32.

Kamada Announces Dividend

The business also recently declared a — dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Monday, March 17th.

Wall Street Analyst Weigh In

KMDA has been the topic of several recent analyst reports. StockNews.com cut Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 25th. Benchmark assumed coverage on shares of Kamada in a research report on Friday, March 21st. They set a “buy” rating and a $15.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research report on Thursday, March 6th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.